(Total Views: 354)
Posted On: 05/30/2018 9:16:19 PM
Post# of 72447
B-OM's potential competitor, AG013 released positive interim safety analysis (not efficacy) and it's stock went up 67%.
Oragenics enrolled just 24 out of 200 patients for their Phase 2 trial so they are way behind B-OM.
"We expect to report top-line results of the completed phase 2 trial in late 2019."
https://www.oragenics.com/news-media/press-re...is-results
Oragenics enrolled just 24 out of 200 patients for their Phase 2 trial so they are way behind B-OM.
"We expect to report top-line results of the completed phase 2 trial in late 2019."
https://www.oragenics.com/news-media/press-re...is-results
(2)
(0)
